D-REV DESIGN FOR THE OTHER NINETY PERCENT
695 MINNESOTA STREET, SAN FRANCISCO, CA 94107 www.d-rev.org

---

Organizations Filed Purposes: D-Rev designs and brings world-class health solutions to the people who need them most. With significant input from users, we design, refine, launch, support, and track products and services to provide quality care in low-resource settings.

D-Rev is a not-for-profit medical technology company whose mission is: To create medical technology for everyone. D-REVS PRODUCTS ARE SOLD IN 71 COUNTRIES, AND HAVE TREATED 817,000 patients. This increase in impact is nearly double D-Rev's impact in 2019.

SMART CPAP: RESPIRATORY DISTRESS SYNDROME AFFECTS 30% OF PREMATURE NEWBORNS AND RESULTS IN NEARLY 100% MORTALITY IF NOT TREATED. D-REV IS DEVELOPING A CONTEXTUALLY-APPROPRIATE STATE-OF-THE-ART CPAP (CONTINUOUS POSITIVE AIR PRESSURE) DEVICE THAT ADDRESSES RESPIRATORY DISTRESS. WE MOVED INTO THE LATE DESIGN PHASE IN 2019.

BRILLIANCE: D-REVS FLAGSHIP LINE OF PRODUCTS TO MANAGE SEVERE JAUNDICE IN NEWBORNS SURPASSED 800,000 BABIES TREATED IN 2019. NOTABLE ACHIEVEMENTS THIS YEAR: D-REV STRENGTHENED THE NEWBORN CARE ECOSYSTEM WITH A NEWBORN HEALTH SYMPOSIUM WHERE WE DISSEMINATED THE FINDINGS OF THE BRILLIANCE IN RWANDA STUDY; THE COST OF PHOTOTHERAPY DEVICES CONTINUES TO DECREASE GLOBALLY.

IMPACT ASSESSMENT: D-REV INVESTS IN MONITORING, EVALUATION, AND ASSESSMENT TO: (1) INFORM OURSELVES AND PARTNERS THROUGH TRANSPARENT AND ACCOUNTABLE MEASUREMENT OF OUR WORK AND OUTCOMES, (2) INFORM OUR PRODUCT DEVELOPMENT AND ITERATION FOR LONG-TERM SUSTAINABLE IMPACT. BRILLIANCE AND REMOTION COMBINED IMPACT TREATED MORE THAN 900,000 PATIENTS.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202023209349301507_public.xml